{"api":{"name":"api.sb","description":"Business-as-Code surface for Startups.Studio","home":"https://api.sb","docs":"https://api.sb/docs","version":"1.0.0"},"$context":"https://api.sb/$context","$type":"FoundingHypothesis","$id":"https://api.sb/founding-hypotheses/fh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1","links":{"self":"https://api.sb/v1/founding-hypotheses/fh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1","canonical":"https://api.sb/founding-hypotheses/fh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1","pool":"https://api.sb/v1/founding-hypotheses"},"foundingHypothesis":{"id":"fh:pharmacists-medication-therapy-review:t-hsa:v1","lens":"AIService","type":"founding-hypothesis","click":{"rubricScores":{"C8_lensFit":0,"C7_magicLensFit":1,"C4_competitorHonesty":1,"C6_crossSlotCoherence":1,"C1_customerSpecificity":1,"C2_problemFrictionRealism":1,"C9_killCriteriaAttestability":1,"C3_approachEngineCoverability":1,"C5_differentiationLoservilleEscape":1},"upperRightLoserville":true},"cellRef":{"id":"work-contexts.org.ai/pharmacists-medication-therapy-review","stableHash":"wcc:pharmacists:medication-therapy-review:document:v1"},"problem":{"slotStatement":"Every time CMS updates a Star Ratings measure, a state Medicaid preferred-drug list shifts, or AHA/ACC guidance revises (e.g. SGLT2 first-line in HFrEF), the CMR letters pharmacists mailed last quarter were written against the OLD rule pack — and the next Part-D program audit surfaces recommendations that contradict current guidance, triggering audit findings the pharmacy director must remediate patient-by-patient with no clean trace of which guideline version applied on which review date."},"approach":{"oneSentence":"A guideline-version-pinned CMR review engine that watches CMS, state PDL, and specialty-society feeds, re-scores every open MTM recommendation against the new rule set within 24 hours of a change, and hands the pharmacist a dated divergence worksheet showing exactly which prior CMRs now conflict with current guidance and why — so the pharmacy director walks into the next Part-D audit with a review-ready version history instead of a remediation backlog."},"customer":{"icpShape":"Director of Pharmacy Services at a municipal/public-utility healthcare entity (company-type-public-utility) — county hospital districts, public health authorities, and state-owned health plans running 10–40 clinical pharmacists who perform CMS MTM Comprehensive Medication Reviews, where the buyer is the Director of Pharmacy Services (or VP Clinical Services) who signs the PO against a quality-program budget and the daily user is the staff clinical pharmacist conducting the CMR.","beachheadShape":"EarlyAdopterJTBD: public hospital district pharmacy departments whose MTM CMR volume spiked after a state-Medicaid formulary refresh and whose last HEDIS/Part-D audit flagged stale beta-blocker/DOAC guidance in CMR letters."},"archetype":"startup-archetypes.org.ai/AIService-Subscription","beachhead":"EarlyAdopterJTBD: public hospital district pharmacy departments whose MTM CMR volume spiked after a state-Medicaid formulary refresh and whose last HEDIS/Part-D audit flagged stale beta-blocker/DOAC guidance in CMR letters.","competitors":{"substitutes":[{"name":"OutcomesMTM (Cardinal Health)","category":"incumbent","uncopyabilityReason":"OutcomesMTM's revenue model is a closed PBM/plan-sponsor contract where CMR templates and intervention libraries are curated centrally and pushed to the pharmacist — its integration depth with plan-sponsor claims feeds means it cannot expose per-review guideline versioning or a pharmacist-owned divergence worksheet without breaking the plan-payer data-sharing contracts that fund the platform. Barrier category: integration-depth."},{"name":"Mirixa (OptumRx)","category":"incumbent","uncopyabilityReason":"Mirixa is distributed through OptumRx's payer network and is effectively a workflow-assignment rail for PBM-sourced MTM cases; the public-utility hospital district is not its economic buyer (the PBM is), so Mirixa cannot prioritize a pharmacy-director-facing audit-remediation feature set without cannibalizing its distribution channel into plan sponsors. Barrier category: distribution-channel."},{"name":"PioneerRx / EnlivenHealth Amplicare MTM module","category":"incumbent","uncopyabilityReason":"Amplicare ships as a community-pharmacy point-of-sale overlay wired to dispensing workflows; retrofitting a retrospective guideline-drift re-scorer that reopens closed CMRs would require a separate longitudinal review datastore and state-licensure posture (clinical advice, not dispense support) that its retail-pharmacy liability posture is not structured to carry. Barrier category: liability-posture."},{"name":"Outside clinical-pharmacy consultant annual rule-pack diff","category":"informal"},{"name":"Lexicomp / Micromedex manual lookup during review","category":"manual-bridge"}]},"studioThesis":"T-HSA","killThreshold":{"K":8,"M":30,"N":7,"rubricItemSet":["C1_customerSpecificity","C2_problemFrictionRealism","C3_approachEngineCoverability","C4_competitorHonesty","C5_differentiationLoservilleEscape","C6_crossSlotCoherence","C7_magicLensFit","C8_lensFit","C9_killCriteriaAttestability"],"verdictPolicy":"all-load-bearing-pass-and-overall-ge-X","loadBearingItemSet":["C1_customerSpecificity","C2_problemFrictionRealism","C3_approachEngineCoverability","C4_competitorHonesty","C5_differentiationLoservilleEscape","C6_crossSlotCoherence","C9_killCriteriaAttestability"],"verdictPolicyVerbatim":"KILL unless every load-bearing rubric item passes per workbook AND overall pass-rate ≥ 7/9 (CASCADE.md §4 Stage 9 commit threshold)."},"lifecycleState":"Active","differentiation":{"twoByTwo":{"xAxis":"Guideline-change reconcile cadence (annual consultant refresh ↔ continuous feed re-scoring within 24h of CMS/PDL/society update)","yAxis":"Scope of re-evaluation (forward-only: new CMRs use new rules ↔ retrospective: previously-closed CMRs are re-scored and flagged when guidance shifts)","winningQuadrant":"Continuous 24-hour reconcile with retrospective re-scoring of already-mailed CMRs, producing a dated divergence worksheet the pharmacy director hands to the Part-D auditor","loservilleEscape":true,"loservilleQuadrant":"Annual consultant rule-pack refresh applied forward-only — the mode OutcomesMTM and the outside-consultant bridge actually operate in today, where a July SGLT2 guideline change does not touch the 4,000 CMRs mailed in Q2 and the audit finds them one by one."}},"unmetRequirements":[],"pricingArchitecture":"usage-meter"},"actions":{},"options":{},"relationships":{"runtimeUnit":"https://api.sb/v1/runtime-units?startupRef=startup%3Afh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1","brand":"https://api.sb/v1/brands?startupId=startup%3Afh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1","listing":"https://api.services/listings?foundingHypothesisRef=fh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1","cell":"https://api.sb/v1/cells/work-contexts.org.ai/pharmacists-medication-therapy-review","thesis":"https://api.sb/v1/theses/T-HSA"},"meta":{"level":"L0","scopes":[]},"user":{"requestId":"a0575b857cd6a8fe","edgeLocation":"a0575b857cd6a8fe","geo":{"country":"US"},"ua":{"browser":"Claude"}},"references":{"total":0,"limit":25,"page":1,"links":{"self":"https://api.sb/v1/founding-hypotheses/fh%3Apharmacists-medication-therapy-review%3At-hsa%3Av1/references"},"items":[]}}